Malaria, along with HIV and Tuberculosis, is one of the three most common
infectious diseases in the world. It has infected human beings for over 50,000
years and may have been a human pathogen throughout the entire history of our
species. An estimated 300 million people suffer from this disease and more
than one million die each year. Eighty percent of cases are located in
Sub-Saharan Africa affecting mainly young children and pregnant women (WHO,
2008). Malaria is a major public health issue commonly associated with
poverty, but it is also a cause of poverty and a major hindrance to economic
development. Malaria related-illnesses and mortality cost Africa' s economy
alone an estimated $12 billion USD per year (Roll Back Malaria).
The cause of malaria was discovered in 1880 by Charles Louis Alphonse Laveran
who identified parasites in the red blood cells of people with the disease and
suggested that malaria was caused by this protozoan. Malaria is caused by
Plasmodium parasites and is transmitted by the female Anopheles mosquito. The
most severe form (cerebral malaria) is due to Plasmodium falciparum, the most
frequent strain in Africa.
Table of Contents
METHODOLOGY
INTRODUCTION
1. BRIEF OUTLINE OF THE MARKET
2. BRIEF OUTLINE OF THE PIPELINE
3. PROTECTION STRATEGIES
3.1. Evolution of patent filings over time
3.2. Priority filings
3.3.Extensions
3.4. Analysis of industrial filings over time
3.5. Study of the granting of US patents
3.6. Study of the granting of European patents
3.7. Study of the granting of Japanese patents
3.8. Evolution in the number of applicants
3.9. Breakdown by IPC codes
4. GENERAL ANALYSIS
4.1. Topology of patents in the sector
4.2. Analysis of the main applicants in the entire portfolio
4.3. Focus on the global strategy of the major industrial applicants
4.4.Collaborations
4.5. Citations between applicants
4.6. Most cited patents
5. FOCUS ON THE CLASSIFIED CHEMOTHERAPEUTIC COMPOUNDS
5.1. General analysis
5.1.1. Breakdown of patent filings over time
5.1.2. Focus on the main chemical classes
5.1.3. Focus on the other chemical classes
5.2.Applicants
5.2.1. Main applicants
5.2.2. Filings by main applicants over time
5.2.3. Topics protected for classified chemotherapeutic compounds
5.2.4. Topics protected for the other classified chemotherapeutic compounds
5.2.5. Emerging applicants
5.3. Inventors
5.3.1. Main inventors
5.3.2. Topics protected for classified chemotherapeutic compounds
5.3.3. Topics protected for other classified chemotherapeutic compounds
5.3.4. Research teams
5.3.5. Experts
5.3.6. Emerging inventors
6. FOCUS ON VACCINES
6.1. General analysis
6.1.1. Patent filings over time
6.1.2. Breakdown of patents by types of vaccines
6.2. Applicants
6.2.1. Main applicants
6.2.2. Topics protected
6.3. Inventors
6.3.1. Main inventors
6.3.2. Topics protected
6.3.3. Research teams
6.3.4. Experts
7. FOCUS ON DIAGNOSTIC
7.1. General analysis
7.1.1. Breakdown of patent filings over time
7.1.2. Breakdown of patents by diagnostic method
7.2. Applicants
7.2.1. Main applicants
7.2.2. Topics protected
7.2.3. Emerging applicants
7.3. Inventors
7.3.1. Main inventors
7.3.2. Topics protected
7.3.3. Research teams
7.3.4. Experts
7.3.5. Emerging inventors
8. FOCUS ON OTHER MALARIA PATENTS
8.1. General analysis
8.1.1. Breakdown of patent filings over time
8.2. Breakdown of other malaria patents
8.3. Applicants
8.3.1. Main applicants
8.3.2. Topics protected
8.4. Inventors
8.4.1. Main inventors
8.4.2. Topics protected
CONCLUSION
APPENDICES
NUMBER OF PATENT FILINGS BY APPLICANTS
NUMBER OF PATENT FILINGS OF COMPANIES PRESENT IN THE PIPELINE
Listo of Figures
FIGURE 1 - NUMBER OF PEOPLE INFECTED BY MALARIA
FIGURE 2 - LIFE CYCLE OF PLASMODIUM PARASITES
FIGURE 3 - TREATMENTS UNDER DEVELOPMENT BY CLASS OF COMPOUNDS
FIGURE 4 - EVOLUTION IN PATENT FILINGS
FIGURE 5 - GEOGRAPHIC DISTRIBUTION OF PRIORITY FILINGS
FIGURE 6 - GEOGRAPHIC DISTRIBUTION OF PRIORITY FILINGS/CLOSE-UP: EUROPE
FIGURE 7 - GEOGRAPHIC DISTRIBUTION OF EXTENSIONS
FIGURE 8 - EVOLUTION OF THE BREAKDOWN OF INDUSTRIAL FILINGS
FIGURE 9 - EVOLUTION OF AVERAGE GRANT TIME FOR US PATENTS
FIGURE 10 - EVOLUTION OF GRANTING OF US PATENTS
FIGURE 11 - EVOLUTION OF GRANTING OF EUROPEAN PATENTS
FIGURE 12 - EVOLUTION OF GRANTING OF EUROPEAN PATENTS
FIGURE 13 - EVOLUTION OF GRANTING OF JAPANESE PATENTS
FIGURE 14 - EVOLUTION OF GRANTING OF JAPANESE PATENTS
FIGURE 15 - EVOLUTION OF THE NUMBER OF APPLICANTS
FIGURE 16 - DISTRIBUTION OF THE 20 MAIN IPC CODES
FIGURE 17 - BREAKDOWN OF THE PORTFOLIO BY APPLICATIONS
FIGURE 18 - MAIN APPLICANTS IN THE ENTIRE PORTFOLIO
FIGURE 19 - BREAKDOWN OF THE MAIN PATENT PORTFOLIO
FIGURE 20 - EXTENSION POLICY FOR THE FIVE MAJOR INDUSTRIAL APPLICANTS
FIGURE 21 - MAJOR COLLABORATIONS AND JOINT FILINGS
FIGURE 22 - MAP OF CITATIONS BETWEEN APPLICANTS
FIGURE 23 - BREAKDOWN OF PATENT FILINGS BY CLASSIFIED CHEMOTHERAPEUTIC
COMPOUNDS OVER TIME
FIGURE 24 - BREAKDOWN OF THE PORTFOLIO BY CHEMICAL CLASSES
FIGURE 25 - BREAKDOWN OF THE OTHER CHEMICAL CLASSES
FIGURE 26 - MAIN APPLICANTS OF CLASSIFIED CHEMOTHERAPEUTIC COMPOUNDS
FIGURE 27 - CLASSIFIED CHEMOTHERAPEUTIC COMPOUNDS BY MAIN APPLICANTS
FIGURE 28- OTHER CLASSIFIED CHEMOTHERAPEUTIC COMPOUNDS BY MAIN APPLICANTS
FIGURE 29 - CLASSIFIED CHEMOTHERAPEUTIC COMPOUNDS BY MAIN INVENTORS
FIGURE 30 - OTHER CLASSIFIED CHEMOTHERAPEUTIC COMPOUNDS BY MAIN INVENTORS
FIGURE 31 - CLASSIFIED CHEMOTHERAPEUTIC COMPOUNDS BY MAIN RESEARCH TEAMS
